Financial Performance - The company achieved operating revenue of CNY 635,047,016.37, representing a year-on-year increase of 23.59%[3] - Net profit attributable to shareholders reached CNY 120,200,356.40, up 54.32% compared to the previous year[3] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 103,053,921.12, reflecting a growth of 50.39%[3] - Basic earnings per share increased to CNY 1.91, a rise of 45.80% year-on-year[3] Assets and Equity - Total assets at the end of the reporting period were CNY 999,216,907.56, an increase of 19.24% from the beginning of the period[3] - Shareholders' equity attributable to the company was CNY 817,416,485.37, up 18.22% from the start of the period[3] Sales and Market Development - The company focused on enhancing sales and market development, leading to steady growth in product sales[6] - The sales of key compound products "复瑞彤" and "波开清" saw significant increases, contributing to improved product structure and higher overall gross margin[6] Cost Management - The company optimized internal management and reduced costs, resulting in lower sales and management expense ratios compared to the previous year[7] Reporting Status - This earnings report is preliminary and has not been audited, with final figures to be confirmed in the annual report[8]
德源药业(832735) - 2022 Q4 - 年度业绩